(MENAFN- GlobeNewsWire - Nasdaq) The hepatitis diagnostics and treatment market offers opportunities through rising prevalence of hepatitis B and C, advancements in diagnostics and antiviral therapies, and expanding healthcare access in Asia-Pacific. North America's strong infrastructure aids its significant market share, while global health initiatives aim to reduce treatment costs.Dublin, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The "Hepatitis Diagnostic and Treatment Market - Forecasts from 2025 to 2030" has been added to ResearchAndMarkets's offering.
The global hepatitis diagnostic and treatment market is set for notable expansion, projected to grow from USD 33.224 billion in 2025 to USD 39.915 billion by 2030, at a compound annual growth rate (CAGR) of 3.74%. This expansion is largely driven by the increasing incidence of hepatitis infections, particularly hepatitis B and C, which are the lead contributors to hepatitis-related mortality. Viral hepatitis, instigated by viruses such as A, B, C, D, E, and G, poses a significant health burden, with B and C being notably prevalent due to their chronic infection nature.
![]()
Key growth drivers include rising levels of alcohol and drug consumption, improved access to therapeutic hepatitis medications, and advancements in diagnostic and treatment technology. The market is buoyed by intensified global initiatives aimed at enhancing hepatitis healthcare provision.
Market Segmentation Analysis
The market is divided into diagnostics and treatment segments. Diagnostic methods encompass blood tests, DNA and RNA testing, liver biopsies, and ultrasounds. These methodologies are crucial for early diagnosis and effective disease management. Treatment options include antiviral medications and injectable alpha interferons for chronic hepatitis B and C, alongside liver transplants for severe cases. While the diagnostic sector is expanding due to increased demand for accurate and accessible testing, the treatment segment benefits from innovations in antiviral therapies.
In terms of disease type, the market is further segmented into Hepatitis A, B, C, and others such as D, E, and G. Hepatitis B and C maintain their dominance due to their high prevalence and chronic nature, particularly in areas with reduced healthcare access. Hepatitis A, in contrast, is less chronic and often preventable, whereas B and C necessitate prolonged management, thus driving demand for advanced therapeutic solutions.
Geographical Insights
North America leads the market, driven by robust healthcare infrastructure, access to novel medications, and heightened awareness. Rapid market growth is anticipated in the Asia-Pacific region, fueled by a high burden of hepatitis B and C and increasing healthcare accessibility in areas like China and eastern Asia. Europe, the Middle East, Africa, and South America also contribute, with strategic efforts varying according to regional disease prevalence and healthcare needs.
Competitive Landscape
The market is highly competitive, featuring key players such as Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences, Inc., Bayer AG, AbbVie Inc., and Janssen Pharmaceuticals, Inc. These companies focus on geographical expansion and the development of innovative treatments, including next-generation antivirals and diagnostic tools. Strategic partnerships and R&D investments play critical roles in meeting unmet needs and adhering to regulatory requirements.
Market Outlook
Poised for significant growth through 2030, the hepatitis diagnostic and treatment market is driven by rising disease prevalence, enhanced drug accessibility, and innovative treatment methods. North America's market dominance and the rapid expansion in Asia-Pacific underscore substantial opportunities. Despite facing challenges such as high treatment costs, global health initiatives are addressing these issues. The market's growth trajectory highlights its essential role in combating chronic viral hepatitis worldwide.
Key Benefits of this Report:
Gain comprehensive market insights covering major and emerging regions with a focus on customer segments, socio-economic factors, and industry verticals. Understand strategic maneuvers employed by key global players for market penetration. Explore dynamic market drivers and trends that will shape future developments. Use insights for strategic decisions to uncover new business streams and revenue opportunities. Suitable for a diverse audience, including startups, research institutions, SMEs, and large enterprises.
Report Coverage:
Historical data from 2020 to 2024 and forecast from 2025 to 2030. Opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis. Competitive positioning, strategies, and market share analysis. Revenue growth and forecast assessment by segments and regions. Company profiling including strategies, products, financial information, and key developments.
Segmentation:
By Type: Blood Tests, DNA Tests, Liver Biopsy, RNA Testing, Liver Ultrasound, Treatment, Drugs, Injectable Alpha Interferons, Liver Transplant. By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Others. By Geography: North America (USA, Canada, Mexico), South America (Brazil, Argentina), Europe (Germany, France, UK, Spain), Middle East and Africa (Saudi Arabia, UAE), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand).
Key Attributes
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment